KOREA WHO
-
-
CEO of Cell Biotech
Chung Myung-jun
Founder of the Leading Probiotics Export Company
-
Last Updated on Jul 16, 2024
-
CEO of Cell Biotech
Copy Url : https://www.koreawho.com/profile/ChungMyungjun- Life Summary
Chung Myung-jun is the CEO of Cell Biotech.
He is dedicated to research and development for 'gut health' and 'developing Korean probiotics.'
He was born on January 5, 1958, in Seoul.
Chung graduated from Yonsei University with a degree in Biology. He earned a master's degree in Microbiology from Seoul National University and a Ph.D. in Biotechnology from the Technical University of Denmark.
He worked at the Central Research Institute of Miwon and Daesang.
In 1995, he founded Cell Biotech and grew it into the company with the most GRAS-registered probiotics, the highest safety certification by the U.S. Food and Drug Administration (FDA), worldwide.
He is expanding the business by developing various disease treatments based on probiotic technology.
#ChungMyungjun #CellBiotech #Probiotics #GutHealth #KoreanProbiotics #FDA #GRAS #Biotechnology #DiseaseTreatment #YonseiUniversity #SeoulNationalUniversity
He is dedicated to research and development for 'gut health' and 'developing Korean probiotics.'
He was born on January 5, 1958, in Seoul.
Chung graduated from Yonsei University with a degree in Biology. He earned a master's degree in Microbiology from Seoul National University and a Ph.D. in Biotechnology from the Technical University of Denmark.
He worked at the Central Research Institute of Miwon and Daesang.
In 1995, he founded Cell Biotech and grew it into the company with the most GRAS-registered probiotics, the highest safety certification by the U.S. Food and Drug Administration (FDA), worldwide.
He is expanding the business by developing various disease treatments based on probiotic technology.
#ChungMyungjun #CellBiotech #Probiotics #GutHealth #KoreanProbiotics #FDA #GRAS #Biotechnology #DiseaseTreatment #YonseiUniversity #SeoulNationalUniversity
- Life Summary
- Career Highlights & Challenges
- · Cell Biotech's Governance Structure
- · Sales Growth Continues in Q1 2024 Due to Increased Exports
- · 'Bitter Melon + Probiotics' Confirmed for Anti-Diabetes and Anti-Obesity Effects
- · Launch of 'DUOLAB Synergy Beauty Pack'
- · Microbiome-Based Colorectal Cancer Drug 'PP-P8' Approved for Phase 1 Clinical Trial
- · Obtained 'GRAS' Certification from the U.S. FDA
- · Development of Korean Vaginal Probiotic
- · Development of Domestic Probiotics that Enhance Protein Absorption
- · Launch of Pet Probiotics
- · Discovery of Probiotics that Enhance Multivitamin Absorption
- · U.S. Patent Acquired for Probiotic Drug Delivery System
- · Launch of Nutritional Supplement Brand DUOLAB
- · Probiotic That Enhances Red Ginseng Absorption Discovered
- · Selected for Ministry of Agriculture, Food and Rural Affairs' 'High Value-Added Food Technology Development Project'
- · Study on Four Bifidobacterium Strains Selected as Cover Paper in Microbiology Journal
- · Completion of Prototype Plant for Colon Cancer Treatment
- · Launch of Cosmetics Brand
- · History of Cell Biotech
- Vision and Goals
- Market and Social Evaluation
- Notable Incidents & Legal Affairs
- Professional Timeline
- Educational Background
- Family & Personal Connections
- Awards & Recognitions
- Additional Information
- Notable Quotations
- Infographic & Photos